CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE ApplicationDecember 21, 2017 2:58 PM